Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 3
1975 8
1976 7
1977 6
1978 2
1979 7
1980 3
1981 1
1982 3
1983 1
1984 2
1985 5
1986 7
1987 8
1988 4
1989 4
1990 3
1991 4
1992 4
1993 3
1994 3
1995 5
1996 10
1997 7
1998 5
1999 7
2000 9
2001 10
2002 7
2003 9
2004 8
2005 9
2006 10
2007 8
2008 11
2009 11
2010 14
2011 13
2012 11
2013 18
2014 19
2015 15
2016 16
2017 13
2018 15
2019 18
2020 15
2021 20
2022 19
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Results by year

Filters applied: . Clear all
Page 1
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y. Janes MR, et al. Among authors: lorenzi mv. Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006. Cell. 2018. PMID: 29373830 Free article.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Among authors: lorenzi mv. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Brehmer D, Beke L, Wu T, Millar HJ, Moy C, Sun W, Mannens G, Pande V, Boeckx A, van Heerde E, Nys T, Gustin EM, Verbist B, Zhou L, Fan Y, Bhargava V, Safabakhsh P, Vinken P, Verhulst T, Gilbert A, Rai S, Graubert TA, Pastore F, Fiore D, Gu J, Johnson A, Philippar U, Morschhäuser B, Walker D, De Lange D, Keersmaekers V, Viellevoye M, Diels G, Schepens W, Thuring JW, Meerpoel L, Packman K, Lorenzi MV, Laquerre S. Brehmer D, et al. Among authors: lorenzi mv. Mol Cancer Ther. 2021 Dec;20(12):2317-2328. doi: 10.1158/1535-7163.MCT-21-0367. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583982 Free PMC article.
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, Sendecki J, Beqiri M, Millar HJ, Packman K, Lorenzi MV, Laquerre S, Moores SL. Vijayaraghavan S, et al. Among authors: lorenzi mv. Mol Cancer Ther. 2020 Oct;19(10):2044-2056. doi: 10.1158/1535-7163.MCT-20-0071. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747419
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM. Moores SL, et al. Among authors: lorenzi mv. Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23. Cancer Res. 2016. PMID: 27216193
Integration of Multimodal Data.
Lorenzi M, Deprez M, Balelli I, Aguila AL, Altmann A. Lorenzi M, et al. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 19. 2023 Jul 23. In: Colliot O, editor. Machine Learning for Brain Disorders [Internet]. New York, NY: Humana; 2023. Chapter 19. PMID: 37988505 Free Books & Documents. Review.
Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Dabbous O, et al. Among authors: lorenzi m. Adv Ther. 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11. Adv Ther. 2019. PMID: 31512141 Free PMC article. No abstract available.
Social regulation of reproduction: control or signal?
Benvenuto C, Lorenzi MC. Benvenuto C, et al. Among authors: lorenzi mc. Trends Ecol Evol. 2023 Nov;38(11):1028-1040. doi: 10.1016/j.tree.2023.05.009. Epub 2023 Jun 28. Trends Ecol Evol. 2023. PMID: 37385846 Free article. Review.
Tumor angiogenesis.
Zerbini G, Lorenzi M, Palini A. Zerbini G, et al. Among authors: lorenzi m. N Engl J Med. 2008 Aug 14;359(7):763; author reply 764. doi: 10.1056/NEJMc081278. N Engl J Med. 2008. PMID: 18703484 No abstract available.
402 results